Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cangene Advances Alzheimer's Disease Research with Technology Developed at UBC

Published: Monday, September 16, 2013
Last Updated: Monday, September 16, 2013
Bookmark and Share
New technology targeting Alzheimer's Disease licensed to Cangene Corporation.

A truly made-in-Canada treatment for one of the world's most devastating diseases could be closer to patients thanks to a new technology targeting Alzheimer's Disease developed at The University of British Columbia (UBC) and licensed to Cangene Corporation (Cangene).

Following the successful research collaboration with the inventor, Dr. Neil Cashman at UBC, Cangene recently obtained commercial rights to the technology platform and plans to advance the program in its pipeline to explore treatments for Alzheimer's Disease, a significant unmet medical need with an increasing burden on health-care systems.

Cangene, with core competencies in the development and commercialization of biologic therapeutics, has established a strong pipeline platform for antibody therapies.

Dr. Cashman's discovery will allow Cangene to advance an immune therapeutic treatment approach to Alzheimer's by targeting the toxic form of Amyloid-beta with the potential to directly impact the disease mechanism of action.

Current treatment options are limited and the number of individuals afflicted with this degenerative disease is growing rapidly as the population ages, currently estimated to be 25 million worldwide.

"We are pleased to have the opportunity to collaborate with Dr. Cashman who is an expert in misfolded protein diseases and help advance his ground-breaking research in Alzheimer's Disease" says Dr. Laura Saward, Cangene's Chief Scientific Officer.

"While this work is in its early stages, it is showing promise for the development of a novel immunotherapy to address this devastating disease and fits Cangene's refocused strategy" adds Dr. Saward.

The Canadian Institute for Health Research (CIHR) is an important sponsor of the Alzheimer's Disease program. The discoveries made by Dr. Cashman were supported by research funding through CIHR and further advanced through a research collaboration between UBC, the federally-funded Prionet Network Centre of Excellence and Cangene, UBC's pharmaceutical industry partner.

UBC and Cangene continue to collaborate on the development of treatments for Alzheimer's Disease with support from CIHR's Proof of Principle Program Phase II.

The joint research program to evaluate the therapeutic potential of the target as a vaccine or antibody therapeutic was successful in the latest competition and CIHR has committed to provide $300,000 in funding over a one year period further cementing this as a made-in-Canada solution that has the potential to address this global problem.

"This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic," says Dr. J.P. Heale, Associate Director of UBC's University-Industry Liaison Office. "The partnerships developed to advance Dr. Cashman's outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos